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Abstract
Background: The airway epithelium (AE) forms the first line of defence against harmful particles and pathogens.
Barrier failure of the airway epithelium contributes to exacerbations of a range of lung diseases that are commonly
treated with Azithromycin (AZM). In addition to its anti-bacterial function, AZM has immunomodulatory effects
which are proposed to contribute to its clinical effectiveness. In vitro studies have shown the AE barrier-enhancing
effects of AZM. The aim of this study was to analyze whether AE damage caused by inhalation of sulfur dioxide
(SO2) in a murine model could be reduced by pre-treatment with AZM.
Methods: The leakiness of the AE barrier was evaluated after SO2 exposure by measuring levels of human serum
albumin (HSA) in bronchoalveolar lavage fluid (BALF). Protein composition in BALF was also assessed and lung
tissues were evaluated across treatments using histology and gene expression analysis.
Results: AZM pre-treatment (2 mg/kg p.o. 5 times/week for 2 weeks) resulted in reduced glutathione-S-transferases
in BALF of SO2 injured mice compared to control (without AZM treatment). AZM treated mice had increased
intracellular vacuolization including lamellar bodies and a reduction in epithelial shedding after injury in addition to
a dampened SO2-induced inflammatory response.
Conclusions: Using a mouse model of AE barrier dysfunction we provide evidence for the protective effects of AZM
in vivo, possibly through stabilizing the intracellular microenvironment and reducing inflammatory responses. Our data
provide insight into the mechanisms contributing to the efficacy of AZM in the treatment of airway diseases.
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Background
Environmental pollutants are often associated with ex-
acerbation of disease, including those linked to cardiac,
skin and respiratory conditions [1, 2]. Air pollution is
comprised of several components, one of the major ones
being sulfur dioxide (SO2), a gas commonly produced
from combustion of sulfur-containing fuels such as coal
as well as from volcanic eruptions [3]. Fine particles
formed from fugitive dust, SO2 and oxygen result in par-
ticulate matter (PM), a primary pollutant and irritant
which, as air pollution increases, leads to an increase in
respiratory and cardiovascular diseases [1].
The lungs, lined with an epithelial layer, are complex
structures responsible for filtering and humidifying air,
facilitating gas exchange, and acting as the first line of
defense against the external environment [4]. The airway
epithelium from the nose, trachea and bronchi through
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to the alveoli, together with the underlying basement
membrane form an effective barrier to prevent pollut-
ants and infectious agents such as bacteria and viruses
from entering the body [5]. Exposure to air pollutants,
both gaseous and PM, can weaken the epithelial barrier,
predispose the respiratory system to infections, and fa-
cilitate both acute and chronic respiratory disorders [6].
Indeed, fine PM have been shown to lead to a weakened
epithelium [7, 8] and are now accepted as a leading con-
tributor to chronic respiratory and cardiovascular dis-
eases [9, 10].
Patients suffering from asthma, COPD and CF are at
greatest risk of exacerbations caused by air pollution such
as SO2 and PMs, along with viruses and bacteria. These pa-
tients often have compromised lung barrier functions [6].
Treatment of patients with acute exacerbations of respira-
tory diseases often involves administration of antibiotics
such as macrolides including AZM [11]. Indeed, a range of
studies have revealed beneficial effects of AZM beyond its
anti-microbial effects that has led to this macrolide being
used for chronic maintenance treatment to prevent exacer-
bations of respiratory diseases, a treatment approach that
whilst effective, increases the risk of bacterial resistance
[11]. AZM has been shown to have multiple disease-
modifying effects of relevance to treating and preventing
exacerbations of respiratory diseases, including immuno-
modulation (reviewed by Parnham et al. [12]).
In addition to the anti-microbial and immunomodulatory
effects of AZM, previous studies by our group and others
have shown that this drug enhances the respiratory epithe-
lial barrier when cultured in air-liquid interface (ALI) cul-
ture [13–15]. Most recently, we demonstrated that AZM
induces a partial epidermal differentiation program in bron-
chial epithelial cells in ALI culture [16]. Histological ana-
lysis demonstrated formation of lamellar bodies (LBs). LBs
are found in lungs, where they contribute to production
and release of pulmonary surfactants, and in skin, where
they contribute to the water barrier, presumably facilitating
the increased barrier function observed in vitro. However,
to date there have been no observations demonstrating
similar barrier enhancing effects of AZM in vivo. In this
study, we have established an in vivo model of epithelial
barrier dysfunction in the airway epithelium using SO2 ex-
posure to investigate whether AZM has barrier protective
functions. We demonstrate that pretreating mice with
AZM prior to SO2 exposure ameliorates AE damage in-
cluding barrier leakiness, reduces the expression of GST de-




Female C57BL/6NTac mice were purchased from Taco-
nic Biosciences, Denmark. Mice were purchased within
the age range of 5–9 weeks, with an average weight of
20 g on arrival. Mice were allowed 1 week of
acclimatization before the start of the study. They were
randomized into treatment groups (6 mice in a group
per cage) and kept in 335 cm2 cages 13 cm deep. Cages
were housed in standardized environments in Scanbur
cabinets. The animals were maintained with a 12-h light
cycle at 23–24 °C and relative air humidity of 40% Mice
were kept on aspen bedding with nesting material, red
polycarbonate hiding material and biting bricks. They
were provided with ad libitum Altromin diet and filtered
drinking water. This study has been approved by the Ice-
landic food and veterinary authority (MAST), Licence
#2018-09-02. The choice of using 6 mice per group was
based on a similar study [17].
AZM treatment
AZM was provided by Recipharm, Uppsala, Sweden. Mice
(n = 6 in each group) were treated p.o. with 2mg/kg AZM
in 5% ethanol in saline 5 times per week for 2 weeks prior
to SO2 exposure. Control animals (n = 6 in each group)
received 5% ethanol in saline for the same duration.
SO2 exposure
Inhalation exposure was regulated using a system from
Electro-Medical Measurement Systems (EMMS, UK). SO2
was purchased as 500 ppm in 80%/20% N2/O2 (synthair)
from ÍSAGA (Reykjavik, Iceland). The inhalation system was
custom-built to facilitate controlled exposure of individual
mice. Mice were placed in individual holding tubes and
placed in a holding tower so that their noses were inside the
tower for inhalation. SO2 was downmixed in air by the sys-
tem to the desired concentration and pumped into the tower
at the top at a rate of 5 L/min. Tower pressure was main-
tained at a positive pressure of 0.3 cm H2O by active moni-
toring and active outflow (vacuum pump). The SO2 was
bubbled through concentrated NaOH in water for scrubbing.
Mice were exposed to 50–400 ppm SO2 for 4 h. After
SO2 exposure, mice were given 1–7 days to recover be-
fore BALF collection and subsequent histological and
molecular analysis of lung tissue. Animal weight was also
monitored before and after exposure to SO2 gas.
BALF collection
BALF was collected 1, 3 or 7 days after SO2 exposure.
Sixty minutes before BALF collection, mice were injected
i.v. via the tail vein with 1 mg HSA in a 100 μl bolus of
saline. Before BALF collection, mice were euthanized
with a mixture of Euthasol vet/Lidocaine. After euthan-
asia, mice were placed in a supine position and the tra-
chea exposed by cutting the skin and moving the
salivary glands. Using sharp forceps, a suture thread was
inserted below the trachea. A small opening was cut in
the trachea and the trachea intubated with a canula. The
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suture was then tied to hold the canula in place. BALF
was collected from two 0.5 ml PBS washes and centri-
fuged at 2000 rpm for 3 min to collect pellet debris.
BALF, free of cellular debris, was divided into three ali-
quots and stored at − 20 °C for future analyses.
ELISA
HSA concentrations in BALF samples were measured by
ELISA (R&D Systems, DY1455) according to the manufac-
turer’s instructions. In short, plates were coated with diluted
anti-HSA antibodies overnight at room temperature (RT)
and then blocked with blocking solution for 1 h at RT. Stan-
dards and samples were then added, incubated, and washed
4x with washing solution. Detection antibodies diluted in
ELISA buffer were then added and incubated for 2 h at RT.
Streptavidin-HRP (1:40 in ELISA buffer) was added and in-
cubated in the dark at RT for 20min. Substrate solution
was then added and incubated in the dark at RT until col-
ored precipitates were evident in most concentrated stan-
dards. Then stop solution was added and plates measured.
Immunohistochemistry
After BALF collection, lungs were harvested for histology.
Lungs were fixed in 3.7% buffered formaldehyde for 24 h
minimum and embedded in paraffin using standardized
procedures. After embedding, slides were prepared and
stained with hematoxylin and eosin for assessment of histo-
pathological effects.
Transmission electron microscopy
Tracheas and lung pieces were fixed in 2.5% glutaraldehyde
for 1–2 h followed by post-fixation in 2% osmium tetroxide
for 1 h and a subsequent phosphate buffer rinse. Samples
were dehydrated in ethanol and uranyl acetate and embed-
ded in resin. 100 nm sections were cut with an Ultramicro-
tome (Leica EM UC7). Sections were stained with lead
citrate (3%, J.T. Baker Chemical Co.) and imaged using a
JEM-1400PLUS PL Transmission Electron Microscope.
Proteomic analysis of BALF samples
BALF was collected 3 days after exposure and pooled
from each animal (n = 6) in the separate treatment
groups and concentrated (Amicon Ultra-15 filter units).
Briefly, approximately 900 μl of pooled BALF was trans-
ferred to a 3 kDa Amicon column and spun as per man-
ufacturer’s instructions. 100 μl of ~ 0.4 mg/ml BALF
samples for each treatment group (n = 1) were for sent
for LFQ analysis by MS to the “FingerPrints” Proteomic
Facility, University of Dundee, UK.
RNA isolation and RNA sequencing
Three days after exposure, mice were sacrificed and tissue
pieces from lung were harvested and stored in RNAlater™
(Invitrogen, ThermoFisher) at − 20 °C until total RNA was
extracted in TRI-Reagent® (Ambion, ThermoFisher) using
gentle MACS™ Dissociator from Miltenyi Biotec in M tubes
(Miltenyi Biotec). RNA samples were shipped to BGI Gen-
omics (Ole Maaloes Vej 3, 2200 København, Denmark) for
RNA sequencing. The RNA transcript expression was quan-
tified with Kallisto version 0.46.1 [18] using the Ensembl
Mus musculus GRCm38 reference transcriptome [19]. Gene
expression estimates were computed with the sleuth R pack-
age v0.30 [20]. Two samples were discarded because of inad-
equate quality (one placebo control and one placebo SO2
treated sample). We measured transcripts that were differen-
tially expressed using Wald test in sleuth, in placebo SO2-
treated mice (n = 2) vs control untreated mice (n = 2), com-
pared to AZM- and (No SO2 exposure, n = 3) SO2-treated
mice (n = 3). Gene set enrichment analysis was performed
with the GSEA software v4.0.1 [21, 22]. Pre-ranked gene lists
were prepared by ordering the genes (one transcript per
gene) by expression difference significance (q-value multi-
plied with the sign of the log-fold change) and tested for en-
richment in the MSigDB hallmark gene set collection [23].
Statistical analysis
For determining statistical significance for mouse weight
and ELISA analysis, a student t-test was utilized and cal-
culated using GraphPad Prism 8.0. Error bars represent
the standard deviation of the means. Calculations for the
statistical significance for the differential gene expression
were calculated using Wald test in sleuth.
Results
Set up and validation of the SO2 exposure system
Inhalation of SO2 was controlled using a custom-built in-
halation system as described in the materials and methods.
Figure 1a shows a diagram of the inhalation system to ex-
pose all animals in a comparable manner, while simultan-
eously preventing SO2 leakage into the environment. The
whole system was kept in a fume hood, except for the input
air- and SO2 containers. Mice were individually placed in
size appropriate inhalation tubes and mounted to the tower
for the duration of the experiment. Laboratory environ-
mental heating was maintained at 26 °C to minimize the
risk of hypothermia to the mice. After exposure, mice were
returned to their cages to recover. Behaviorally, mice briefly
demonstrated slight signs of distress, for example, hunching
in corners of cages or hiding. Low mobility and lethargy
were observed for about 60min after exposure, accompan-
ied by grooming. Afterwards, behavior returned to normal.
On average, mice exposed to SO2 lost 8% of their body
weight in the first 24 h after exposure, compared with no
change in mice that were not exposed. Mice placed in the
exposure system, but not exposed to SO2 for 4 h lost on
average 3.5% body weight. Weight mostly recovered within
3 days and was fully recovered after 7 days (Fig. 1b).
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SO2 exposure causes no obvious histological changes, but
increased airway epithelial permeability which can be
reduced by AZM pre-treatment
Figure 1c, top row, demonstrates hematoxylin and eosin
staining of histological sections of lung tissues exposed
for 4 h to 100 ppm SO2, 1 day after exposure. No obvious
histological changes were observed, and lungs appeared
healthy.
One day after SO2 challenge, HSA in BALF was mea-
sured by ELISA and a significant (p = 0.004, n = 5 mice in
each group) increase in HSA in BALF was observed in
mice exposed to 100 ppm SO2 for 4 h (Fig. 1d),
Fig. 1 Subtle damage to airway epithelium and increased leakiness occurs after SO2 exposure which is mitigated by pretreatment with AZM. a. Schematic
depiction of the SO2 exposure system. 500 ppm SO2 is downmixed to the desired concentration in a positive pressure control unit. Downmixed gas is
passed over the animals in a tower, ensuring constant and comparable exposure to all animals. Up to 12 animals were treated simultaneously. Outflow gas
was passed through a NaOH solution for scrubbing SO2 gas from the air mixture. Outflow pressure was monitored in order to maintain a small positive
pressure (1 cm H2O) in the exposure tower. b. Weight changes in mice exposed to 100 ppm SO2 for 4 h. Overall, mice placed in the tower lost a significant
(8%; *** p < 0.0001) amount of body weight after exposure to SO2 in the inhalation system. This weight loss did not occur in control animals. Weight loss
was recovered quickly, and mice reached their starting weights within a week after exposure. Data are means of ± SD of n = 18 for SO2 exposed mice and
n = 4 for control mice. c. No histological changes were observed after exposure to SO2 H&E stained lung tissue. No histological changes were observed. Scale
bars are 500 μm. d. HSA in BALF is increased upon SO2 exposure. Increased HSA in SO2 exposed mice compared with control mice was seen, as determined
by ELISA. Average HSA in control and SO2 treated mice was 143 and 440 ng/ml, respectively. Data are represented as box and whiskers plots with boxes
encompassing the 25th – 75th quartiles, and whiskers demonstrating minimum and maximum values. n = 5 mice in each group. p = 0.0044. e. AZM
pre-treatment results in decreased epithelial permeability to HSA. Mice orally gavaged with 2mg/kg AZM 5 times per week had a trend for reduced HSA
concentration in BALF observed after SO2 exposure when compared to placebo mice, indicating a protective effect. Average HSA in control, SO2 and AZM,
SO2 groups was 238, 350 and 150 ng/ml, respectively. Data are represented as box and whiskers plots with boxes encompassing the 25th – 75th quartiles,
and whiskers minimum and maximum values. n = 5 observations per treatment group. p = 0.13
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demonstrating an increased leakiness of the lungs, despite
the apparent lack of visual damage, indicating sub-
histological changes. When we compared HSA levels and
histology in mice that were allowed 1-, 3- or 7-days recov-
ery time, differences were minimal, therefore 3 days post
SO2 exposure was selected for analyses for the remainder
of the study. We hypothesized that 3 days would allow
partial repair and we could detect the beneficial effects of
pre-treatment with AZM. We pre-treated mice with 2
mg/kg AZM, dosed 5 times per week via oral gavage for 2
weeks. We then exposed these mice to 100 ppm SO2 for 4
h followed by a 3-day recovery time before BALF collec-
tion. HSA ELISA comparing SO2 exposed mice with SO2
exposed mice that received AZM indicated a trend (p =
0.13, n = 5 mice in each group) that the leakiness was at-
tenuated as demonstrated by reduced HSA concentrations
in BALF in the AZM treated group (Fig. 1e).
SO2 exposure results in increased glutathione-S-
transferase response that is reduced in AZM pre-treated
mice
To extend the observations of epithelial permeability
assessed by HSA measurements, we performed prote-
omic mass spectrometry (MS) of BALF to assess pro-
teins and peptides in SO2 exposed mice compared to
unexposed mice. We probed the dataset for proteins and
peptides that were present in greater amounts in BALF
from mice exposed to SO2 and discovered that 6 mem-
bers of the glutathione-S-transferase (GST) superfamily
were shown to be increased (Fig. 2a).
Interestingly, the GST family of proteins that showed
increased expression in Fig. 2a were all considerably less
expressed in mice pre-treated with AZM (Fig. 2b).
Gene set enrichment analysis reveals attenuated
inflammatory response to SO2 challenge as a result of
AZM pre-treatment
Whole lung RNA lysates were prepared and RNA tran-
script expression analysed via RNA sequencing. Analyz-
ing the RNA sequencing data through gene set
enrichment analysis (GSEA) showed that exposing the
mice to SO2 resulted in a positive correlation with in-
flammatory gene pathways. The three pathways with the
highest positively correlated normalized enrichment
scores (NES) were interferon alpha response (NES: 0.53,
p-val <0.001), interferon gamma response (NES: 0.41, p-
val <0.001) and allograft rejection (NES: 0.34, <0.001)
gene sets (Fig. 3a), all immune related pathways. The
volcano plot presented in Fig. 3b shows the genes over-
represented in the gene set with the highest NES, inter-
feron alpha response, in green. The volcano plot of the
data obtained from SO2 exposed mice that had been
pre-treated with AZM, shows a lower expression of
these genes (Fig. 3c). Figure 3d presents a heatmap
Fig. 2 SO2 exposure results in increased expression of members of the Glutathione S Transferase family. a. Glutathione S transferase is increased in
BALF in SO2 exposed mice. BALF samples were analysed by mass spectrometry. Of the samples showing dramatic changes from controls, 6 GST
analogs were detected and demonstrated to be increased in BALF samples of SO2 exposed mice. Data represent a single measurement from a
pooled sample from six mice in each treatment group. b. The increased GST concentration in BALF seen in SO2 exposed mice is attenuated by pre-
treatment with AZM. The six GSTs shown previously all had reduced BALF concentrations when mice were pre-treated with AZM. Data represent a
single measurement from a pooled sample from six mice in each treatment group
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comparison of the interferon alpha genes involved. Ana-
lysis of several genes from the interferon alpha gene pre-
sents a similar pattern, i.e. that exposure to SO2 is
followed by a significant (p ≤ 0.001) upregulation of the
gene, but when mice were pre-treated with AZM, the
gene expression stays closer to the levels observed in un-
exposed, untreated conditions and no significant differ-
ence is seen (Fig. 3e).
AZM increases vesicle and lamellar body formations in
both SO2 exposed and non-exposed mice
Tracheal and alveolar tissue samples from the mice were
collected 3 days after exposure. The tracheal epithelium
of the SO2 exposed mice showed some signs of shed-
ding, evidenced by unevenness of the epithelial layer and
cells appearing to peel off from the top of the layer
(Fig. 4a red arrows). When viewing tissues from AZM
treated mice, there were accumulations of vesicles not
seen in the same amounts as in the untreated controls
(Fig. 4a yellow arrows). SO2 exposed mice that had re-
ceived AZM pre-treatment accumulated even more vesi-
cles and the layer was consistently more even than in
the non-treated, SO2 exposed mice (Fig. 4a). Upon im-
aging the alveolar region of the mouse tissue samples, it
was evident that the alveolar type II cells of the AZM
pre-treated mice were accumulating lamellar bodies (Fig.
4b yellow arrows). Lamellar bodies were also seen in the
untreated samples, but they did not accumulate to the
same degree (Fig. 4b).
Discussion
In this study, we have administered SO2 gas to mice in a
controlled manner to expose all test animals evenly and
reproducibly. We have demonstrated that SO2 can be
used as a challenging agent in mice to induce subtle air-
way epithelial damage and leakiness measured by in-
creased epithelial shedding and blood-derived human
serum albumin (HSA) extravasation into BALF. Pre-
treating mice with AZM 2 weeks prior to SO2 exposure
reduced epithelial shedding, concentrations of HSA in
BALF and mitigated pro-inflammatory gene responses,
demonstrating the barrier enhancing role of AZM be-
yond the antibiotic activity of this drug, as has been pre-
viously shown in vitro [13, 14, 16].
Air pollution from natural disasters (i.e. volcanic emis-
sions), and those caused by human influences (i.e. forest
fires) are a major concern to governments throughout
the world [24]. Sulfuric oxides are continuously pro-
duced in vast quantities through the burning of fossil
fuels for electricity and transportation [25, 26], as well as
in sporadic disasters such as volcanic eruptions. Sulfur
dioxide (SO2) is a major component of air pollution and
is transformed into sulfuric acid in water, and when in-
haled can cause damage to the respiratory system,
leading to inflammation and barrier failure [27, 28]. This
makes the study of SO2 and how it affects pulmonary
function highly important and clinically relevant. With
the increasing evidence for the lung protective capabil-
ities of AZM [29–32], we decided to pre-treat mice with
AZM before applying short term SO2 exposure and
analyze the effect of AZM on prevention or attenuation
of initial damage responses and the subsequent immu-
nomodulatory effects on the epithelial barrier.
Intravenous administration of HSA into experimental
animals has been widely used as a marker for vascular
permeability and to study other biological problems such
as drug delivery [33]. Albumin, for instance, has been
used to target clarithromycin to the lung through
albumin-derived microsphere carriers [33]. There has,
however, been a lack of surrogate markers to measure
airway epithelial barrier leakiness and in this study, we
used HSA as a marker for barrier failure. By injection of
HSA into the tail vein 1 h prior to BALF harvesting, we
were able to measure concentrations of HSA that had
leaked into BALF using ELISA. Exposing mice to SO2
resulted in increased concentrations of HSA in BALF
which were reduced when mice were pre-treated with
AZM.
We also analyzed whether native markers of oxidative
stress were changed during SO2 exposure and performed
mass spectrometric analysis of BALF which showed in-
creased expression of several GSTs. GSTs are an integral
part of the glutathione redox system, mitigating oxida-
tive damage to tissues, including damage induced by sul-
furic compounds [34]. The observation that these
proteins were upregulated on SO2 exposure indicated
that while the gross histology of the mouse lungs was
unaltered, there was an active biochemical response to
oxidative damage in the lungs of SO2 exposed mice. In
addition, we were able to reduce the GST responses by
pre-treating mice with AZM for 2 weeks. A reduction in
the GST responses indicates that the SO2-induced oxi-
dative damage was lowered in the AZM treated mice.
This is in keeping with reports that AZM inhibits hyp-
oxic lung injury in neonatal rats and ozone-induced lung
inflammation in healthy human volunteers [35, 36].
SO2 is a well-known inducer of inflammation in the re-
spiratory system [37]. Thus, SO2 exposure has been shown
to increase expression of pro-inflammatory cytokines such
as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-
α) in mouse lungs [38]. Furthermore, nitric oxide synthase
and intercellular cell adhesion molecule-1 (ICAM-1) levels
have been shown to be increased in the lungs of rats fol-
lowing SO2 inhalation [39]. These data are in line with
our findings that increased expression of genes positively
correlated with inflammation-related pathways and were
mitigated when mice were pretreated with AZM. Expres-
sion analysis of RNA from lung tissue indicates that SO2
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Fig. 3 Pretreatment with AZM reduces the expression of SO2 induced inflammatory interferon alpha responsive genes. a. Gene set enrichment
analysis of positively correlated pathways with the highest normalized enrichment scores (NES) as a result of SO2 challenging of the mice. Top three
most positively correlated pathways were the inflammation related interferon alpha response, interferon gamma response and allograft rejection.
FDR is false discovery rate and NOM p-val is nominal p-value. b. Volcano plot of differentially expressed genes comparing gene expression of non-
exposed vs SO2 exposed mice. Genes in the interferon alpha response pathway are colored green. c. Volcano plot of differentially expressed genes
comparing gene expression of non-exposed vs SO2 exposed mice that had been pre-treated with AZM. Genes in the interferon alpha response
pathway are colored green. d. Heatmap of genes that were positively correlated to the interferon alpha gene set. On the left is shown the differential
gene expression as a result of SO2 exposure. On the right is shown the differential expression as result of SO2 exposure in AZM pre-treated mice.
e. Boxplot of selected genes in the interferon alpha gene set. All genes show a similar pattern of higher expression as a result of SO2 exposure. The
AZM pre-treatment of the unexposed as well as the SO2 exposed resulted in similar expression levels as the unexposed, untreated mice. Boxplot
made with the R package ggplot/geom. Data are represented as box and whiskers plots with boxes encompassing the 25th – 75th quartiles, and
whiskers demonstrating 1.5 Interquartile range above and below. N = 3, except for placebo (N = 2). *** p ≤ 0.001
Fig. 4 AZM pre-treatment protects against epithelial shedding and increases lamellar body formation. a. Electron microscope images of the
tracheal epithelium. SO2 exposed mice show shedding of the epithelium as seen when comparing SO2 +/−. Shedding is seen by the top of the
layer peeling of and an uneven layer indicated by red arrows. Mice that had been pre-treated with AZM, but not exposed to SO2 showed
accumulations of vesicles in the epithelial layer. SO2 exposed, AZM pre-treated mice also showed these vesicle formations, even to a greater
extent, and the epithelial layer did not show shedding. All the epithelial layers presented some small vesicle formations, but the increases as a
result of AZM treatment were distinct throughout all the samples. Yellow arrows point to examples of vesicle formations. Shown are
representative images taken of 3 replicates. Top scale bars are 10 μm and lower scale bars are 2 μm. b. Electron microscope images of the alveolar
region of the lungs. No discernible difference was seen in the control vs the SO2 exposed mice. Lamellar bodies were observed in most of the
alveolar type II cells in all the samples. Only in the AZM pre-treated mouse samples were accumulations of lamellar bodies detected. Yellow
arrows point to examples of lamellar bodies. Shown are representative images taken of 3 replicates. Top scale bars are 10 μm and lower scale
bars are 2 μm
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exposure resulted in increased expression of inflammatory
related gene sets and/or pathways. The pathway with the
highest normalized enrichment score was the interferon
alpha response. By focusing on the genes that were posi-
tively correlated with the interferon alpha response path-
way on SO2 exposure, we noticed that these genes were
not as highly expressed when mice had been pre-treated
with AZM before SO2 exposure. Interestingly, expression
of several additional immune-related genes followed the
same trend, that is, increased expression as a result of SO2
challenge, but close to control expression in AZM pre-
treated mice, regardless of SO2 exposure, as observed pre-
viously in epithelial cells stimulated with purulent exudate
[40]. This indicates immunomodulatory effects of AZM,
where the pre-treated mice show attenuated inflammatory
responses to the SO2 challenge. Our results indicate that
AZM should be considered as a candidate for treatment
of lung injury similar to that which occurs in conditions
such as acute respiratory distress syndrome (ARDS). In
fact, AZM used as adjunctive therapy in patients with
ARDS has been shown to be beneficial [41]. Collectively,
these data demonstrate that a single exposure of SO2 can
induce inflammation in mouse lung tissue and that this
inflammatory response is dampened if mice are pretreated
with AZM. As excessive inflammatory responses are hall-
marks of progressive lung diseases such as ARDS, it is im-
portant to find drugs that dampen the response [42].
Further investigation into the molecular function of AZM
in the airway epithelium is of great importance for several
lung diseases including both life-threating conditions such
as ARDS and COPD.
Using ALI cultured human bronchial epithelial cells,
we recently demonstrated that AZM treatment induces
epidermal differentiation, as shown by the expression of
skin associated markers evaluated by gene expression
analysis [16]. This study was based on the investigation
of bronchial epithelial cell lines cultured in air-liquid
interface conditions where AZM was added directly to
the culture media, whereas the in vivo conditions we
evaluated in the present study are much more compli-
cated and represent changes following AZM adminis-
trated p.o. Nonetheless, the findings presented here
show that after p.o. administration, AZM appears to
protect the integrity of the respiratory epithelial barrier.
In ALI cultures, AZM induces formation of multivesicu-
lar bodies and LBs [16], structures which are only found
in vivo in keratinocytes generating the water barrier in
skin [43]; and in the lungs, associated with club and al-
veolar type II cells [44]. Interestingly, an increase in the
formation of LBs was confirmed in mice pre-treated
with AZM, where alveolar type II cells were seen to form
accumulations of LBs and in the tracheal epithelial layer,
where an accumulation of vacuoles were observed.
Whether formation of LBs contributes to the barrier
enhancement of AE is currently not known. Pre-treated
mice that had been exposed to SO2 showed less cellular
shedding than untreated mice exposed to SO2, leading
us to the conclusion that AZM confers barrier enhance-
ment in the lungs.
Of interest, AZM has been previously shown to attenu-
ate tobacco smoke-induced oxidative stress-related cell
viability reduction in cultured human lung cells [45], thus
supporting a protective role in an in vitro application.
An important limitation of our model is that in the
current study, we only mimicked intermittent exposure of
SO2, as opposed to prolonged exposure. As such, we rep-
resent the protective effects of AZM over a short SO2 ex-
posure time period, resembling a volcanic exposure or a
forest fire, but not chronic exposure like that associated
with city pollution. Our data indicate however that AZM
could have protective effects for individuals with weak-
ened lung function with a foreseeable risk of exposure to
SO2, such as during seasonal changes in city pollution or
during travel. The results presented here would benefit
from supporting studies using prolonged SO2 exposure.
Conclusions
Collectively, we have demonstrated in this study that pre-
treating mice with AZM before exposure to SO2 gas
reduces the damage to the respiratory epithelium, includ-
ing reduced epithelial leakiness and oxidative stress, and a
dampening of the inflammatory response. This study and
previous in vitro studies demonstrate the need for non-
antibacterial drugs that maintain the disease modifying
effects of AZM with less risk of causing bacterial re-
sistance. The airway epithelium is the first line of defense
against various pathogens and external hazardous particles
such as SO2 and therefore strengthening the epithelium in
patients with barrier dysfunction is of great importance,
particularly for protection of immunodeficient or other-
wise compromised patients from hazardous components
in the air, such as pollutants and infectious agents like
bacteria and viruses. Our data corroborate the notion that
AZM provides this sort of protection, and that prophylac-
tic administration of AZM to patients suffering from
respiratory diseases, or preferably modified derivatives of
AZM lacking antibacterial activity may be a feasible
treatment option to reduce exacerbations.
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